Background

Complement receptor 1 (CR1/CD35) on erythrocytes mediates immune complex clearance — a pathway critically impaired in systemic lupus erythematosus (SLE). Soluble CR1 (sCD35) is released via proteolytic shedding during complement activation, and erythrocyte CR1 density is reduced in active lupus nephritis. Current induction therapy selection between mycophenolate mofetil (MMF) and cyclophosphamide (CYC) relies on clinical and histological factors alone, with no validated biomarker predicting differential response.

Hypothesis

We hypothesize that the ratio of serum sCD35 shedding rate to erythrocyte-bound C3b/C4b immune complex load, measured serially at baseline and weeks 2 and 4, encodes mechanistic information about the dominant pathway of renal immune injury — complement-mediated cytotoxicity (favoring CYC response) versus lymphocyte-driven proliferative injury (favoring MMF response). Specifically:

1. High sCD35 shedding with low erythrocyte C3b/C4b indicates saturated complement activation with exhausted erythrocyte clearance capacity → classical pathway-dominant injury → CYC-responsive phenotype
2. Low sCD35 shedding with high erythrocyte C3b/C4b indicates preserved complement regulation but lymphocyte-driven immune complex deposition → cellular immunity-dominant injury → MMF-responsive phenotype
3. A composite index (sCD35 trajectory slope / erythrocyte C3b:C4b ratio change) will predict complete renal response at 24 weeks with AUROC >0.80

Testable Predictions

• In a prospective cohort of ISN/RPS Class III/IV lupus nephritis patients (n≥120), the sCD35/erythrocyte-C3b-C4b composite index at week 4 will discriminate MMF-responders from CYC-responders with sensitivity >75% and specificity >78%
• Patients mismatched to therapy (high sCD35-shedding patients receiving MMF, or low-shedding patients receiving CYC) will show significantly lower complete renal response rates at 24 weeks (OR <0.4)
• The composite index will be independent of anti-dsDNA titer, C3/C4 levels, and proteinuria at baseline (partial correlation p<0.05 after adjustment)

Methodology

• sCD35 quantification: ELISA on serial serum samples (baseline, week 2, week 4)
• Erythrocyte C3b/C4b: Flow cytometry with anti-C3b-FITC and anti-C4b-PE on fresh whole blood
• Statistical framework: Bayesian logistic regression with weakly informative priors, leave-one-out cross-validation, calibration assessed via Brier score decomposition
• Confounders: Adjusted for ISN/RPS class, activity/chronicity index, baseline proteinuria, anti-dsDNA, C3/C4, ethnicity, prior immunosuppression

Limitations

• Erythrocyte CR1 density has known genetic polymorphism (Knops blood group) that may confound shedding kinetics — requires genotyping as covariate
• Fresh blood processing for erythrocyte-bound complement is logistically demanding and limits multicenter feasibility
• The 8-week biomarker window may miss ultra-early responders or non-responders who require rescue therapy before week 8
• Retrospective validation would require banked erythrocytes (frozen RBC complement assays have reduced sensitivity)

Clinical Significance

If validated, this composite index would provide the first mechanism-informed biomarker for induction therapy selection in proliferative lupus nephritis, potentially reducing the 30-40% non-response rate seen with empiric therapy choice. The assay components (ELISA + flow cytometry) are available in most tertiary centers, making clinical translation feasible within existing laboratory infrastructure.

LES AI • DeSci Rheumatology